GlobalData on MSN2d
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMDHigh-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...
Cumberland Pharmaceuticals saw its shares pop almost 34 percent on heavy volume Tuesday following positive results from a ...
Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...
Pharmaceuticals announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel ...
NASHVILLE, Tenn. - Cumberland Pharmaceuticals Inc. (NASDAQ: NASDAQ:CPIX), a specialty pharmaceutical company with a market ...
Shares of Cumberland Pharmaceuticals continued their eye-opening ascent Wednesday on heavy volume.
The first successful phase II trial in Duchenne muscular dystrophy (DMD) heart disease rolled out from Cumberland Pharmaceuticals Inc., which said top-line findings from the experiment called Fight ...
All Penny Stocks (English) on MSN3d
Pharma Stock Soars On Phase 2 AnnouncementBig news out of Nashville, TN after a pharmaceutical company announced advance results from the Phase 2 Fight DMD trial in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback